Results: 2

1.
Fig. 2

Fig. 2. From: A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

Progression-free and overall survival times. a Progression-free survival (Intent to treat population). b Overall survival (Intent to treat population)

Matthew H. Kulke, et al. Cancer Chemother Pharmacol. 2011 August;68(2):293-300.
2.
Fig. 1

Fig. 1. From: A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

Observed percentage change in sum of tumor longest diameters from screening to minimum post-dose sum (radiologically evaluable population, n = 28)

Matthew H. Kulke, et al. Cancer Chemother Pharmacol. 2011 August;68(2):293-300.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk